INSTITUT CURIE
🇫🇷France
- Country
- 🇫🇷France
- Ownership
- Private
- Established
- 1909-01-01
- Employees
- 1K
- Market Cap
- -
- Website
- http://www.curie.fr
Study of Tumor and Blood Samples From Women With Breast Cancer
- Conditions
- Breast Cancer
- First Posted Date
- 2009-05-12
- Last Posted Date
- 2010-12-01
- Lead Sponsor
- Institut Curie
- Target Recruit Count
- 180
- Registration Number
- NCT00897728
- Locations
- 🇫🇷
Institut Curie Hopital, Paris, France
Radiation Therapy With or Without Temozolomide in Treating Women With Brain Metastases and Breast Cancer
Phase 2
- Conditions
- Breast CancerMetastatic Cancer
- Interventions
- Radiation: radiation therapy
- First Posted Date
- 2009-04-03
- Last Posted Date
- 2009-08-26
- Lead Sponsor
- Institut Curie
- Target Recruit Count
- 100
- Registration Number
- NCT00875355
- Locations
- 🇫🇷
Institut Curie Hopital, Paris, France
Cranial Radiotherapy or Intensive Chemotherapy With Hematopoietic Stem Cell Rescue for Primary Central Nervous System Lymphoma in Young Patients
Phase 2
Active, not recruiting
- Conditions
- Primary Central Nervous System Lymphoma
- Interventions
- Radiation: cranial radiotherapyDrug: intensive chemotherapy and hematopoietic stem cell rescue
- First Posted Date
- 2009-03-18
- Last Posted Date
- 2019-02-05
- Lead Sponsor
- Institut Curie
- Target Recruit Count
- 140
- Registration Number
- NCT00863460
- Locations
- 🇫🇷
GH Pitié-Salpétrière, Paris, France
🇫🇷Hôpital Bretonneau, Tours, France
🇫🇷CHR Argenteuil, Argenteuil, France
Test Semiquantitative Prostate Specific Antigen (PSA)
Not Applicable
Completed
- Conditions
- Prostate CancerProstatic NeoplasmsProstatic Diseases
- Interventions
- Other: PSA assay
- First Posted Date
- 2009-03-02
- Last Posted Date
- 2017-08-28
- Lead Sponsor
- Institut Curie
- Target Recruit Count
- 94
- Registration Number
- NCT00853710
- Locations
- 🇫🇷
Centre Rene Huguenin, Saint Cloud, France
Sunitinib as Second-Line Therapy in Treating Patients With Locally Advanced or Metastatic Transitional Cell Cancer
Phase 2
Completed
- Conditions
- Bladder CancerTransitional Cell Cancer of the Renal Pelvis and Ureter
- First Posted Date
- 2008-11-17
- Last Posted Date
- 2011-05-17
- Lead Sponsor
- Institut Curie
- Target Recruit Count
- 80
- Registration Number
- NCT00792025
- Locations
- 🇫🇷
Centre Rene Huguenin, Saint Cloud, France
🇫🇷Hopital Foch, Suresnes, France
Chlorhydrate of Ropivacaine and Breast Cancer Surgery
Phase 4
Completed
- Conditions
- Pain,PostoperativeBreast Neoplasms
- Interventions
- Drug: Chlorhydrate de RopivacaineOther: placebo
- First Posted Date
- 2006-08-31
- Last Posted Date
- 2017-11-06
- Lead Sponsor
- Institut Curie
- Target Recruit Count
- 260
- Registration Number
- NCT00370240
- Locations
- 🇫🇷
René Huguenin Center, Saint-Cloud, France
© Copyright 2025. All Rights Reserved by MedPath